GSTM1 and anemia: The loss to follow-up (LTFU) rate of 24% among the ZDV group as compared to 14.6% in the non-ZDV group was statistically significant, p<0.01, with a documented incidence of severe anaemia in the LTFU group at last recorded Hb.